Cyclopharm (ASX:CYC) has taken a significant step forward in its United States expansion, securing a multi-site agreement with the University of Pennsylvania Health System, one of the country’s most respected academic healthcare networks.
The deal spans 11 clinical locations across Pennsylvania and New Jersey and marks a meaningful advance in the company’s strategy to build scale and recurring revenue in key regional markets.
The agreement begins with the immediate installation of Technegas systems at two high-profile facilities, the Hospital of the University of Pennsylvania and the Perelman Centre for Advanced Medicine. These initial deployments are expected to generate near-term revenue while establishing a strong clinical presence within a top-tier hospital environment. Over time, the remaining nine sites in the network are scheduled for installation, creating a dense cluster of operations within a single integrated health system.
Each installation generates upfront revenue and supports an ongoing stream of income from consumables used in patient procedures, along with annual service and support fees. The contract runs for an initial three years and includes the potential to expand into additional affiliated sites, reinforcing the long-term commercial opportunity.
The University of Pennsylvania Health System is widely recognised for its influence in clinical research and advanced imaging, making it a valuable reference network for broader adoption. Establishing Technegas across multiple sites within such a system strengthens Cyclopharm’s credibility and is expected to support wider uptake, not only for pulmonary embolism diagnosis but also for emerging applications in respiratory and oncology-related conditions.
The deal also reflects a broader shift in Cyclopharm’s US strategy, which is focused on moving from individual site installations to network-wide adoption within large healthcare systems. By focusing on integrated delivery networks, the company aims to increase utilisation, improve operating leverage, and build sustainable recurring revenue.
Chief executive James McBrayer described the agreement as a milestone, highlighting the importance of multi-site contracts in driving scalable growth and deepening institutional relationships. With a strong foothold in a high-profile academic system, Cyclopharm is positioning itself for further expansion across the mid-Atlantic and northeastern United States, where regional density and clinical influence can strengthen its commercial momentum.